Literature DB >> 33188391

Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer's disease.

Kathy Y Liu1, Suzanne Reeves1, Kirsty E McAleese2, Johannes Attems2, Paul Francis3,4, Alan Thomas2, Robert Howard1.   

Abstract

There is clinical overlap between presentations of dementia due to limbic-predominant age-related TDP-43 encephalopathy (LATE) and Alzheimer's disease. It has been suggested that the combination of Alzheimer's disease neuropathological change (ADNC) and LATE neuropathological changes (LATE-NC) is associated with greater neuropsychiatric symptom burden, compared to either pathology alone. Longitudinal Neuropsychiatric Inventory and psychotropic medication prescription data from neuropathologically diagnosed pure ADNC (n = 78), pure LATE-NC (n = 14) and mixed ADNC/LATE-NC (n = 39) brain bank donors were analysed using analysis of variance and linear mixed effects regression models to examine the relationship between diagnostic group and neuropsychiatric symptom burden. Nearly all donors had dementia; three (two pure LATE-NC and one pure ADNC) donors had mild cognitive impairment and another two donors with LATE-NC did not have dementia. The mixed ADNC/LATE-NC group was older than the pure ADNC group, had a higher proportion of females compared to the pure ADNC and LATE-NC groups, and had more severe dementia versus the pure LATE-NC group. After adjustment for length of follow-up, cognitive and demographic factors, mixed ADNC/LATE-NC was associated with lower total Neuropsychiatric Inventory and agitation factor scores than pure ADNC, and lower frontal factor scores than pure LATE-NC. Our findings indicate that concomitant LATE pathology in Alzheimer's disease is not associated with greater neuropsychiatric symptom burden. Future longitudinal studies are needed to further investigate whether mixed ADNC/LATE-NC may be protective against agitation and frontal symptoms in dementia caused by Alzheimer's disease or LATE pathology.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

Entities:  

Keywords:  Alzheimer’s disease; LATE; TDP-43; limbic; neuropsychiatric symptom

Year:  2020        PMID: 33188391     DOI: 10.1093/brain/awaa315

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  5 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

2.  Differences in Symptomatic Presentation and Cognitive Performance Among Participants With LATE-NC Compared to FTLD-TDP.

Authors:  Merilee A Teylan; Charles Mock; Kathryn Gauthreaux; Jessica E Culhane; Gregory Jicha; Yen-Chi Chen; Kwun C G Chan; Walter A Kukull; Peter T Nelson; Yuriko Katsumata
Journal:  J Neuropathol Exp Neurol       Date:  2021-10-01       Impact factor: 3.685

3.  Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study.

Authors:  Myuri Ruthirakuhan; Zahinoor Ismail; Nathan Herrmann; Damien Gallagher; Krista L Lanctôt
Journal:  Alzheimers Dement       Date:  2022-02-01       Impact factor: 16.655

4.  TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death.

Authors:  Marina Buciuc; Nirubol Tosakulwong; Mary M Machulda; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; R Ross Reichard; Joseph E Parisi; Dennis W Dickson; Bradley F Boeve; David S Knopman; Ronald C Petersen; Keith A Josephs
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

5.  Multifocal Transcranial Direct Current Stimulation Modulates Resting-State Functional Connectivity in Older Adults Depending on the Induced Current Density.

Authors:  Kilian Abellaneda-Pérez; Lídia Vaqué-Alcázar; Ruben Perellón-Alfonso; Cristina Solé-Padullés; Núria Bargalló; Ricardo Salvador; Giulio Ruffini; Michael A Nitsche; Alvaro Pascual-Leone; David Bartrés-Faz
Journal:  Front Aging Neurosci       Date:  2021-11-26       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.